Veracyte Shares Drop 56% Following Third-Quarter Results and Revised 2026 Revenue Outlook
Veracyte (VCYT), a molecular diagnostics company specializing in cancer care, experienced a significant stock selloff on Thursday. The shares plummeted by approximately 56%, dropping $29.18 to close at $23.34 during the final half hour of trading. The sharp decline was triggered by the company's third-quarter financial results and a subsequent update to its revenue outlook for 2026. The market reacted negatively to the revised guidance, leading to intense selling pressure.
Tickers: $VCYT
Topics: earnings report molecular diagnostics revenue guidance stock selloff